Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
Sell
33
GNOM Quote, Financials, Valuation and Earnings
Last price:
$9.84
Seasonality move
:
-14.08%
Day range:
$9.83 - $10.00
52-week range:
$9.52 - $12.53
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
95.9K
Avg. volume:
75.7K
1-year change:
-15.08%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- |
|
EDOC
Global X Telemedicine & Digital Health ETF
|
-- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GNOM
Global X Genomics & Biotechnology ETF
|
$9.98 | -- | -- | -- | $0.00 | 0% | -- |
|
AGNG
Global X Aging Population ETF
|
$30.75 | -- | -- | -- | $0.10 | 0.74% | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
$24.91 | -- | -- | -- | $0.24 | 0.96% | -- |
|
EDOC
Global X Telemedicine & Digital Health ETF
|
$10.22 | -- | -- | -- | $0.00 | 0% | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
$29.39 | -- | -- | -- | $0.00 | 0% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$67.85 | -- | -- | -- | $0.01 | 0.05% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | 2.318 | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | 1.009 | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | 1.890 | -- | -- |
|
EDOC
Global X Telemedicine & Digital Health ETF
|
-- | 1.935 | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | 1.788 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 1.301 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
AGNG
Global X Aging Population ETF
|
-- | -- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- | -- |
|
EDOC
Global X Telemedicine & Digital Health ETF
|
-- | -- | -- | -- | -- | -- |
|
HTEC
ROBO Global Healthcare Technology & Innovation ETF
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
Global X Genomics & Biotechnology ETF vs. Competitors
-
Which has Higher Returns GNOM or AGNG?
Global X Aging Population ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat Global X Aging Population ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- AGNGGlobal X Aging Population ETF-- -- -- -
What do Analysts Say About GNOM or AGNG?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Aging Population ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than Global X Aging Population ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than Global X Aging Population ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 AGNGGlobal X Aging Population ETF0 0 0 -
Is GNOM or AGNG More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.125, which suggesting that the stock is 12.532% more volatile than S&P 500. In comparison Global X Aging Population ETF has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.927%.
-
Which is a Better Dividend Stock GNOM or AGNG?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Global X Aging Population ETF offers a yield of 0.74% to investors and pays a quarterly dividend of $0.10 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. Global X Aging Population ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or AGNG?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than Global X Aging Population ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than Global X Aging Population ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while Global X Aging Population ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for Global X Aging Population ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- AGNGGlobal X Aging Population ETF-- -- -- --
-
Which has Higher Returns GNOM or BBC?
Virtus LifeSci Biotech Clinical Trials ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat Virtus LifeSci Biotech Clinical Trials ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -
What do Analysts Say About GNOM or BBC?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Clinical Trials ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than Virtus LifeSci Biotech Clinical Trials ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than Virtus LifeSci Biotech Clinical Trials ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 -
Is GNOM or BBC More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.125, which suggesting that the stock is 12.532% more volatile than S&P 500. In comparison Virtus LifeSci Biotech Clinical Trials ETF has a beta of 1.043, suggesting its more volatile than the S&P 500 by 4.293%.
-
Which is a Better Dividend Stock GNOM or BBC?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Virtus LifeSci Biotech Clinical Trials ETF offers a yield of 0.96% to investors and pays a quarterly dividend of $0.24 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Clinical Trials ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or BBC?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than Virtus LifeSci Biotech Clinical Trials ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Clinical Trials ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for Virtus LifeSci Biotech Clinical Trials ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- --
-
Which has Higher Returns GNOM or EDOC?
Global X Telemedicine & Digital Health ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat Global X Telemedicine & Digital Health ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- EDOCGlobal X Telemedicine & Digital Health ETF-- -- -- -
What do Analysts Say About GNOM or EDOC?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Telemedicine & Digital Health ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than Global X Telemedicine & Digital Health ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than Global X Telemedicine & Digital Health ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 EDOCGlobal X Telemedicine & Digital Health ETF0 0 0 -
Is GNOM or EDOC More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.125, which suggesting that the stock is 12.532% more volatile than S&P 500. In comparison Global X Telemedicine & Digital Health ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GNOM or EDOC?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Global X Telemedicine & Digital Health ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. Global X Telemedicine & Digital Health ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or EDOC?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than Global X Telemedicine & Digital Health ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than Global X Telemedicine & Digital Health ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while Global X Telemedicine & Digital Health ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for Global X Telemedicine & Digital Health ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- EDOCGlobal X Telemedicine & Digital Health ETF-- -- -- --
-
Which has Higher Returns GNOM or HTEC?
ROBO Global Healthcare Technology & Innovation ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat ROBO Global Healthcare Technology & Innovation ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- -
What do Analysts Say About GNOM or HTEC?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand ROBO Global Healthcare Technology & Innovation ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than ROBO Global Healthcare Technology & Innovation ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than ROBO Global Healthcare Technology & Innovation ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 HTECROBO Global Healthcare Technology & Innovation ETF0 0 0 -
Is GNOM or HTEC More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.125, which suggesting that the stock is 12.532% more volatile than S&P 500. In comparison ROBO Global Healthcare Technology & Innovation ETF has a beta of 1.070, suggesting its more volatile than the S&P 500 by 6.985%.
-
Which is a Better Dividend Stock GNOM or HTEC?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ROBO Global Healthcare Technology & Innovation ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. ROBO Global Healthcare Technology & Innovation ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or HTEC?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than ROBO Global Healthcare Technology & Innovation ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than ROBO Global Healthcare Technology & Innovation ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while ROBO Global Healthcare Technology & Innovation ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for ROBO Global Healthcare Technology & Innovation ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- HTECROBO Global Healthcare Technology & Innovation ETF-- -- -- --
-
Which has Higher Returns GNOM or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to Global X Genomics & Biotechnology ETF's net margin of --. Global X Genomics & Biotechnology ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GNOMGlobal X Genomics & Biotechnology ETF-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About GNOM or PBE?
Global X Genomics & Biotechnology ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Global X Genomics & Biotechnology ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe Global X Genomics & Biotechnology ETF is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings GNOMGlobal X Genomics & Biotechnology ETF0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is GNOM or PBE More Risky?
Global X Genomics & Biotechnology ETF has a beta of 1.125, which suggesting that the stock is 12.532% more volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.819, suggesting its less volatile than the S&P 500 by 18.07%.
-
Which is a Better Dividend Stock GNOM or PBE?
Global X Genomics & Biotechnology ETF has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Invesco Biotechnology & Genome ETF offers a yield of 0.05% to investors and pays a quarterly dividend of $0.01 per share. Global X Genomics & Biotechnology ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GNOM or PBE?
Global X Genomics & Biotechnology ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. Global X Genomics & Biotechnology ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, Global X Genomics & Biotechnology ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Global X Genomics & Biotechnology ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How High Will Airbnb Stock Go?
Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…
Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 43x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
57
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
64
ARQQ alert for Dec 27
Arqit Quantum [ARQQ] is down 6.46% over the past day.
Buy
64
QMCO alert for Dec 27
Quantum [QMCO] is up 2.42% over the past day.
Buy
65
ALGS alert for Dec 27
Aligos Therapeutics [ALGS] is down 3.74% over the past day.
